<DOC>
	<DOC>NCT00171730</DOC>
	<brief_summary>Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. This study will assess the long-term safety and efficacy of pasireotide in patients with acromegaly.</brief_summary>
	<brief_title>An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Patients who have completed all four treatment regimens in the core study CSOM230B2201 and achieved biochemical control in GH and IGF1 levels after at least one month of pasireotide administration at any of the three doses Patients who did not experience any unacceptable adverse events or tolerability issues during the core study CSOM230B2201 Patients who experienced or developed compression of the optic chiasm causing any visual field defect during the core study CSOM230B2201 Patients who required a surgical intervention for relief of any sign or symptom associated with tumor compression during the core study CSOM230B2201 Patients who experienced or developed congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation or acute myocardial infraction during the core study CSOM230B2201 Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Pasireotide</keyword>
	<keyword>GH</keyword>
	<keyword>IGF-1</keyword>
</DOC>